Vancomycin Pediatric Dose — Antimicrobial Dosing Guide
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine precursors, disrupting peptidoglycan cross-linking. It is a first-line agent for serious infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. In pediatrics, it is widely used for bacteremia, pneumonia, skin and soft-tissue infections, meningitis, and ventriculitis.
Pediatric Dosing
- General infections: 15 mg/kg/dose IV every 8 hours
- Meningitis / Ventriculitis: 15 mg/kg/dose IV every 6 hours
- Adult reference dose: 1000 mg IV every 12 hours
The per-dose amount is the same in both regimens; the dosing interval is shortened to every 6 hours for CNS infections to achieve higher sustained drug exposure in the CSF.
Worked example — 20 kg child (general infection): 20 kg × 15 mg/kg = 300 mg IV every 8 hours.
Worked example — 20 kg child (meningitis): 20 kg × 15 mg/kg = 300 mg IV every 6 hours.
Consult institutional protocol for weight-based maximum single-dose capping and AUC-guided monitoring targets.
Indications and Clinical Context
Vancomycin is indicated for confirmed or suspected serious gram-positive infections where beta-lactam resistance is a concern, including MRSA bacteremia, hospital-acquired pneumonia, complicated skin and soft-tissue infections, and septic arthritis or osteomyelitis. The more frequent every-6-hour interval for meningitis and ventriculitis reflects the limited CNS penetration of vancomycin and the need for higher, sustained serum concentrations to achieve adequate CSF drug levels. Standard infectious disease and PICU guidelines recommend vancomycin as empiric therapy for bacterial meningitis in combination with a third-generation cephalosporin pending culture and sensitivity results.
Dose individualization based on pharmacokinetic/pharmacodynamic (PK/PD) principles — specifically AUC24/MIC targeting — is now the preferred monitoring strategy per current ASHP/IDSA/SIDP consensus guidelines and should guide ongoing dose adjustments in clinical practice.
Administration and Monitoring
Vancomycin is administered exclusively by the intravenous (IV) route for systemic infections. Each dose should be infused over a minimum of 60 minutes (or longer for doses >500 mg) to minimize the risk of infusion-related reactions, including Red Man Syndrome — a non-immune-mediated histamine release characterized by flushing, erythema, and hypotension. Slowing the infusion rate typically resolves this reaction. IO administration may be used in emergency resuscitation scenarios when IV access is unavailable; consult institutional protocol.
- Therapeutic monitoring: AUC-guided monitoring is preferred over trough-only monitoring; consult pharmacy for sampling strategy.
- Renal function: Vancomycin is renally cleared; dose interval adjustment is required in renal impairment.
- Nephrotoxicity and ototoxicity: Monitor serum creatinine regularly and assess for signs of hearing impairment with prolonged courses or concomitant nephrotoxic agents.
- Extravasation risk: Vancomycin is a vesicant; ensure line patency before and during infusion.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.